Celldex Therapeutics, Inc. (CLDX) Gross margin 2016–2025
Celldex Therapeutics, Inc. (CLDX) gross margin by fiscal year — reported gross profit divided by reported revenue.
87.1%FY2025 · since FY2016: 76.4% → 87.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 87.1% | -10.1 pp |
| FY2024 | 97.2% | +1.5 pp |
| FY2023 | 95.6% | -0.1 pp |
| FY2022 | 95.8% | -2.1 pp |
| FY2021 | 97.8% | +0.5 pp |
| FY2020 | 97.3% | +0.1 pp |
| FY2019 | 97.2% | +4.5 pp |
| FY2018 | 92.7% | -1.8 pp |
| FY2017 | 94.5% | +18.1 pp |
| FY2016 | 76.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CLDX financial trends
CLDX RevenueCLDX Net incomeCLDX Net marginCLDX Gross profitCLDX Operating incomeCLDX Operating marginCLDX Operating cash flowCLDX Free cash flowCLDX Capital expendituresCLDX Return on equityCLDX Stock buybacksCLDX Dividends paidCLDX Total assetsCLDX Total liabilitiesCLDX Shareholders’ equityCLDX overview →